KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) Consolidated Net Income (2025)

Takeda Pharmaceutical has reported Consolidated Net Income over the past 1 years, most recently at $1.4 billion for Q4 2025.

  • For Q4 2025, Consolidated Net Income changed N/A year-over-year to $1.4 billion; the TTM value through Mar 2026 reached $1.4 billion, changed N/A, while the annual FY2026 figure was $2.2 billion, 37.29% up from the prior year.
  • Consolidated Net Income was $1.4 billion for Q4 2025 at Takeda Pharmaceutical.
  • Across five years, Consolidated Net Income topped out at $1.4 billion in Q4 2025 and bottomed at $1.4 billion in Q4 2025.